Vor Biopharma (VOR) Q3 2026 earnings summary

Executive summary

• UPSTREAM MG Phase 3 enrollment is complete; topline data are expected in H1 2027, with ocular MG and Sjögren’s disease programs advancing.

• Cash, cash equivalents and marketable securities totaled $481.6M at Sept. 30, 2026, and are projected to fund operations into early 2029.

• Q3 net loss was $86.7M vs. $812.7M in Q3 2025, primarily reflecting a smaller warrant-liability fair-value expense.

Financial highlights

• Q3 2026 R&D expense was $34.5M vs. $14.1M in Q3 2025; G&A was $23.9M vs. $14.0M.

• Q3 total operating expenses and operating loss were each $58.4M; 9M totals were each $141.5M.

• 9M 2026 net loss was $369.1M vs. $2,418.8M in 9M 2025; 9M R&D fell $224.3M, mainly because 2025 included a $222.6M telitacicept license-acquisition charge.

• Revenue remained $0; no product-sale revenue is expected in the near term, if ever.

Outlook and guidance

• UPSTREAM MG topline data are anticipated in H1 2027; UPSTREAM OMG enrollment and first patient dosing are anticipated in H1 2027.

• Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital needs into early 2029, based on the current operating plan and assumptions that may change.

• R&D expenses are expected to increase significantly as clinical programs advance; G&A costs are also expected to rise with development needs and public-company compliance.

• Additional capital will be needed; potential sources include equity, debt, grants, collaborations or strategic transactions, with dilution and other financing risks.